WGS — GeneDx Holdings Corp. Stock Price, Chart & AI Report

Negative Aug 1, 2026 • 15:27 UTC GlobeNewswire Inc. • Rosen Law Firm

WGS DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (WGS) for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operational efficiencies. The lawsuit claims defendants knew of significant problems with Fabric's viability that would negatively impact the business. Investors with losses exceeding $100K are encouraged to join the class action before the August 3, 2026 lead plaintiff deadline.

WGS securities class action GeneDx Holdings Corp. Fabric acquisition misrepresentation investor losses lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging misrepresentations and omissions regarding the Fabric acquisition. Defendants are accused of knowingly or recklessly disregarding significant problems with Fabric's viability that negatively impacted the business, resulting in investor losses.

Negative Aug 1, 2026 • 07:16 UTC GlobeNewswire Inc. • Rosen Law Firm

מועד אחרון לתביעה הייצוגית נגד ב-WGS ביום שני: רוזן, יועץ מהימן למשקיעים, קורא למשקיעי GeneDx Holdings Corp שספגו הפסדים העולים על 100,000 דולר לקבל ייצוג משפטי לפני המועד החשוב ב-3 באוגוסט במסגרת תביעה ייצוגית בניירות ערך – WGS

Rosen Law Firm announces a securities class action lawsuit against GeneDx Holdings Corp (WGS) for alleged false statements regarding the Fabric acquisition. The firm claims GeneDx made misleading statements about cost reduction and operational synergies that never materialized, causing investor losses. The deadline to join the class action is August 3, 2026.

WGS class action lawsuit securities fraud false statements Fabric acquisition investor losses GeneDx Holdings Corp

Sentiment note

The company is the subject of a securities class action lawsuit alleging false and misleading statements about the Fabric acquisition's financial benefits. Defendants allegedly knew of or recklessly ignored significant issues with Fabric's viability that negatively impacted GeneDx's business and operations, resulting in investor losses.

Negative Jul 31, 2026 • 10:55 UTC GlobeNewswire Inc. • Robbins Geller Rudman & Dowd Llp

MONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

GeneDx Holdings Corp. (WGS) investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements regarding the viability of its Fabric Genomics acquisition. GeneDx's stock dropped over 49% on May 4, 2026 after revealing a significant drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss directly attributable to Fabric Genomics.

WGS ADMA VIA securities fraud class action lawsuit lead plaintiff Fabric Genomics acquisition impairment loss

Sentiment note

GeneDx faces a securities fraud class action lawsuit alleging false and misleading statements about the Fabric Genomics acquisition. The company experienced a 49% stock price drop following disappointing Q1 2026 results, including margin compression, reduced earnings guidance, and a significant impairment charge related to the acquisition.

Negative Jul 30, 2026 • 15:48 UTC GlobeNewswire Inc. • Claimsfiler

GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

GeneDx Holdings Corp. faces a securities class action lawsuit for failing to disclose material information between April 16, 2025 and May 4, 2026. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, lowered full-year guidance from $540-$550M to $475-$490M, and took a $31.2M impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on the announcement. Investors with losses exceeding $100,000 have until August 3, 2026 to file lead plaintiff applications.

WGS securities fraud class action lawsuit material information disclosure gross margin decline impairment loss revenue guidance reduction lead plaintiff deadline

Sentiment note

The company is facing securities fraud allegations for failing to disclose material information, reported significant operational deterioration (gross margin decline from 74% to 69%), missed revenue targets, substantially reduced full-year guidance, and recorded a major impairment loss on a key acquisition. The 49.2% stock price decline reflects severe investor losses and loss of confidence.

Negative Jul 30, 2026 • 02:30 UTC GlobeNewswire Inc. • Rosen Law Firm

WGS DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGS

Rosen Law Firm reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors who purchased stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when defendants knew of significant viability problems that would negatively impact the business.

WGS securities class action lead plaintiff deadline misrepresentation Fabric acquisition investor damages

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding the Fabric acquisition's impact on business operations and financials. Defendants allegedly knew of significant problems that would negatively impact the company but made false positive statements to investors.

Negative Jul 29, 2026 • 02:52 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities fraud class action lawsuit for failing to disclose material information about its Fabric Genomics acquisition performance. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, and took a $31.2 million impairment loss, resulting in a 49.2% stock price decline. Investors who purchased shares between April 16, 2025 and May 4, 2026 can file lead plaintiff applications by August 3, 2026.

WGS securities fraud class action lawsuit acquisition impairment stock decline material misrepresentation revenue guidance gross margin decline

Sentiment note

Company faces securities fraud allegations for failing to disclose material information about acquisition performance, resulting in a 49.2% stock price decline, missed revenue estimates, reduced guidance, and a $31.2 million impairment loss on the Fabric Genomics acquisition.

Negative Jul 27, 2026 • 22:11 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

GENEDX HOLDINGS DEADLINE AUGUST 3rd: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company made false statements about Fabric Genomics and overstated the durability of reimbursement rates. On May 4, 2026, GeneDx revealed a $57.5 million operational loss, lowered 2026 revenue guidance by $65 million, and took a $31.3 million write-down on Fabric Genomics. The stock price fell approximately 50% from $67.93 to $34.51 per share. Investors have until August 3, 2026 to apply as lead plaintiff.

WGS class action lawsuit securities fraud misleading statements Fabric Genomics reimbursement rates goodwill write-down revenue guidance reduction

Sentiment note

The company is facing a class action lawsuit for alleged securities fraud involving false statements about business operations. Additionally, the company reported significant financial deterioration including a $57.5 million operational loss, $65 million revenue guidance reduction, $31.3 million asset write-down, and a 50% stock price collapse, indicating serious operational and financial challenges.

Negative Jul 26, 2026 • 17:15 UTC GlobeNewswire Inc. • Rosen Law Firm

WGS FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGS

A securities class action lawsuit has been filed against GeneDx Holdings Corp. (WGS) for allegedly making false statements regarding the Fabric acquisition's impact on the company's financials and operations. Investors who purchased GeneDx common stock between April 16, 2025 and May 4, 2026 may be entitled to compensation. The deadline to serve as lead plaintiff is August 3, 2026.

WGS securities class action GeneDx Holdings Corp. Fabric acquisition misrepresentation investor compensation lead plaintiff deadline

Sentiment note

The company is the subject of a securities class action lawsuit alleging misrepresentations and omissions regarding the Fabric acquisition's impact on business operations and financials. Defendants allegedly made false statements about cost reduction and efficiency improvements that did not materialize, causing investor damages.

Negative Jul 26, 2026 • 00:06 UTC GlobeNewswire Inc. • Hagens Berman Sobol Shapiro Llp

WGS 9-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline

A securities fraud class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company misled investors about the strategic and financial benefits of its Fabric Genomics acquisition. On May 4, 2026, GeneDx disclosed missed revenue estimates, slashed full-year guidance, and recorded a $31.2 million impairment charge on Fabric, causing the stock to plummet 49.2% in a single session. The lead plaintiff deadline is August 3, 2026.

WGS securities fraud class action lawsuit Fabric Genomics acquisition misrepresentation impairment charge stock collapse lead plaintiff deadline

Sentiment note

The company is accused of materially false and misleading statements regarding the Fabric Genomics acquisition's benefits. The stock crashed 49.2% following corrective disclosures revealing missed estimates, slashed guidance, and a $31.2 million impairment charge wiping out 94% of the acquisition's cash value, destroying billions in shareholder value.

Negative Jul 24, 2026 • 18:37 UTC GlobeNewswire Inc. • Hagens Berman Sobol Shapiro Llp

WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline

A securities fraud class action has been filed against GeneDx Holdings Corp. (NASDAQ: WGS) alleging the company misled investors about the strategic and financial benefits of its Fabric Genomics acquisition. On May 4, 2026, GeneDx disclosed missed revenue estimates, slashed full-year guidance, and recorded a $31.2 million impairment charge on Fabric, causing the stock to plummet 49.2% in a single session. The lead plaintiff deadline is August 3, 2026.

WGS securities fraud class action lawsuit Fabric Genomics acquisition misrepresentation impairment charge stock collapse missed guidance

Sentiment note

The company is accused of materially false and misleading statements regarding the Fabric Genomics acquisition's benefits. The stock crashed 49.2% following corrective disclosures of missed revenue estimates, slashed guidance, and a $31.2 million impairment charge, destroying billions in shareholder value.

Negative Jul 22, 2026 • 02:24 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

GeneDx Holdings Corp. faces a securities class action lawsuit for allegedly failing to disclose material information about its acquisition performance. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, and disclosed a $31.2 million impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% following the May 4, 2026 announcement, with the company lowering full-year revenue guidance from $540-$550 million to $475-$490 million.

WGS WGSWW securities fraud class action lawsuit acquisition impairment revenue miss margin decline stock decline

Sentiment note

Company faces securities fraud allegations for failing to disclose material information about acquisition performance. Significant operational deterioration evidenced by margin compression (74% to 69%), missed revenue targets, substantial impairment charges ($31.2M), and dramatic guidance reduction. Stock declined 49.2% on disclosure, indicating severe loss of investor confidence.

Negative Jul 21, 2026 • 16:55 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GeneDx Holdings Corp. of Class Action Lawsuit and Upcoming Deadlines – WGS

Pomerantz Law Firm has filed a class action lawsuit against GeneDx Holdings Corp. alleging securities fraud and unlawful business practices. The lawsuit stems from GeneDx's May 2026 announcement of disappointing Q1 results, including a significant drop in adjusted gross margin from 74% to 69%, reduced earnings guidance, and a $31.3 million impairment loss related to its Fabric Genomics acquisition. GeneDx's stock price fell 49.20% following the announcement.

WGS WGSWW class action lawsuit securities fraud GeneDx Holdings Fabric Genomics acquisition impairment loss stock price decline

Sentiment note

GeneDx faces a class action lawsuit for alleged securities fraud, reported significant margin compression (74% to 69%), reduced earnings guidance ($540-555M to $475-490M), a substantial $31.3M impairment charge on the Fabric Genomics acquisition, and experienced a severe 49.20% stock price decline.